Continuing Medical Education: Internal Medicine CME: Primary Care CME: New Advances in Inflammatory Bowel Disease: Scripps Conference Services & CME: San Diego, CA: September 11-12, 2010
Continuing Medical Education: Internal Medicine CME: Obgyn CME: Primary Care CME: New Advances in Inflammatory Bowel Disease: Scripps Conference Services & CME: San Diego, CA: September 11-12, 2010
CME Sponsor:
Scripps Conference Services & CME
Location:
Hyatt Regency La Jolla at Aventine
San Diego, CA
Course Directors/Instructors:
David M. Roseman, MD
Former Chief of Staff
M. Jonathan Worsey, MD
Colon and Rectal Surgeon
Guest Faculty:
Maria T. Abreu, MD, Professor of Medicine
Ashwin N. Ananthakrishnan, MD, Division of Gastroenterology and Hepatology
Russell D. Cohen, MD, Associate Professor of Medicine
Marla C. Dubinsky, MD, Pediatric Inflammatory Bowel Disease Center
Andrew F. Ippoliti, MD, Director for Clinical Affairs and Administration
Shervin Rabizadeh, MD, Pediatric Gastroenterology
Miguel D. Regueiro, MD, Associate Professor of Medicine
Feza M. Remzi, MD, Department of Colorectal Surgery
David T. Rubin, MD, Associate Professor of Medicine
Corey A. Siegel, MD, Assistant Professor of Medicine
William J. Tremaine, MD, Professor of Medicine
Number of Credits:
A maximum of 10 AMA PRA Category 1 Credits™
California State Board of Registered Nurses accepts AMA PRA Category 1 Credits
The American Academy of Physicians Assistants accepts Category 1 Credit from AMA PRA Category 1 CME organizations accredited by the ACCME
Registration Fee:
Through August 7
$225 - Physicians
$175 - Nurses/Fellows/Residents/Military
August 8 - September 8
$250 - Physicians
$200 - Nurses/Fellows/Residents/Military
On-Site After September 8
$275 - Physicians
$225 - Nurses/Fellows/Residents/Military
Detailed Description:
The New Advances in Inflammatory Bowel Disease course will highlight the latest concepts relating to the science and microbiology of IBD and examine the latest diagnostic and treatment options for patients living with the disease. Coinfections, disease complications and special population considerations will also be discussed. The course will be taught by nationally recognized experts who are actively involved in clinical trials and studies related to the management and treatment of IBD. The course will offer practical, evidence based information for physicians to implement in their own practice to improve the quality of life for their afflicted patients.
This course is designed for physicians and other health care professionals involved in the care of patients with inflammatory bowel disease. Conference highlights include:
• Expanded two-day curriculum
• Plenary talks from industry leading experts
• Extended question and answer time with expert faculty
• Interactive case presentations and discussion
• Networking opportunities
Learning Objectives:
• Discuss the microbiology and genetics of inflammatory bowel disease.
• Incorporate appropriate diagnostic methods for inflammatory bowel disease as illustrated in case presentations.
• Develop treatment plans for patients with complex and poorly responsive disease.
• Evaluate current treatment options for IBD including biotics, biologics, and immunomodulators.
• Integrate screening and treatment strategies for extra-intestinal manifestations and co-infections in IBD.
• Employ strategies for managing adolescent and non-compliant patients.
• Assess surgical options for treatment of inflammatory bowel disease.
Scripps Conference Services & CME
Location:
Hyatt Regency La Jolla at Aventine
San Diego, CA
Course Directors/Instructors:
David M. Roseman, MD
Former Chief of Staff
M. Jonathan Worsey, MD
Colon and Rectal Surgeon
Guest Faculty:
Maria T. Abreu, MD, Professor of Medicine
Ashwin N. Ananthakrishnan, MD, Division of Gastroenterology and Hepatology
Russell D. Cohen, MD, Associate Professor of Medicine
Marla C. Dubinsky, MD, Pediatric Inflammatory Bowel Disease Center
Andrew F. Ippoliti, MD, Director for Clinical Affairs and Administration
Shervin Rabizadeh, MD, Pediatric Gastroenterology
Miguel D. Regueiro, MD, Associate Professor of Medicine
Feza M. Remzi, MD, Department of Colorectal Surgery
David T. Rubin, MD, Associate Professor of Medicine
Corey A. Siegel, MD, Assistant Professor of Medicine
William J. Tremaine, MD, Professor of Medicine
Number of Credits:
A maximum of 10 AMA PRA Category 1 Credits™
California State Board of Registered Nurses accepts AMA PRA Category 1 Credits
The American Academy of Physicians Assistants accepts Category 1 Credit from AMA PRA Category 1 CME organizations accredited by the ACCME
Registration Fee:
Through August 7
$225 - Physicians
$175 - Nurses/Fellows/Residents/Military
August 8 - September 8
$250 - Physicians
$200 - Nurses/Fellows/Residents/Military
On-Site After September 8
$275 - Physicians
$225 - Nurses/Fellows/Residents/Military
Detailed Description:
The New Advances in Inflammatory Bowel Disease course will highlight the latest concepts relating to the science and microbiology of IBD and examine the latest diagnostic and treatment options for patients living with the disease. Coinfections, disease complications and special population considerations will also be discussed. The course will be taught by nationally recognized experts who are actively involved in clinical trials and studies related to the management and treatment of IBD. The course will offer practical, evidence based information for physicians to implement in their own practice to improve the quality of life for their afflicted patients.
This course is designed for physicians and other health care professionals involved in the care of patients with inflammatory bowel disease. Conference highlights include:
• Expanded two-day curriculum
• Plenary talks from industry leading experts
• Extended question and answer time with expert faculty
• Interactive case presentations and discussion
• Networking opportunities
Learning Objectives:
• Discuss the microbiology and genetics of inflammatory bowel disease.
• Incorporate appropriate diagnostic methods for inflammatory bowel disease as illustrated in case presentations.
• Develop treatment plans for patients with complex and poorly responsive disease.
• Evaluate current treatment options for IBD including biotics, biologics, and immunomodulators.
• Integrate screening and treatment strategies for extra-intestinal manifestations and co-infections in IBD.
• Employ strategies for managing adolescent and non-compliant patients.
• Assess surgical options for treatment of inflammatory bowel disease.
